Results 31 to 40 of about 17,111 (223)
FGF23 as a calciotropic hormone [PDF]
F1000Research, 2015 Maintaining mineral metabolism requires several organs and hormones. Fibroblast growth factor 23 (FGF23) is a phosphatonin produced by bone cells that reduces renal production of calcitriol – 1,25(OH) 2 D 3 – and induces phosphaturia.
María E. Rodríguez-Ortiz +1 more
openaire +2 more sources
World Journal of Nephrology, 2017 Systemic inflammation is a recognized feature in chronic kidney disease (CKD). The role of systemic inflammation in the pathogenesis of vascular calcification was recently settled. FGF23 was recently accused as a direct stimulus of systemic inflammation.
Sharaf El Din, Usama A A +2 more
openaire +2 more sources
Clinical Journal of the American Society of Nephrology, 2010 Chronic kidney disease (CKD) predisposes to cardiovascular disease (CVD), but the pathophysiologic mechanisms that drive this powerful association remain poorly defined despite intense investigation. The inability of randomized trials to demonstrate a benefit in patients with CKD of interventions that are known to reduce major cardiovascular events in ...
openaire +2 more sources
Frontiers in Cell and Developmental Biology, 2022 Enhanced fibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney and heart disease. Experimentally, FGF23 directly induces cardiac hypertrophy and vice versa cardiac hypertrophy stimulates
Fiona Eitner +10 more
doaj +1 more source
Journal of the Endocrine Society, 2022 Parathyroid hormone (PTH) increases fibroblast growth factor 23 (FGF23), mediated both by protein kinase A (PKA) and Wnt signaling, and decreases expression of sclerostin, a Wnt antagonist derived from osteocytes.
Yuki Nagata +6 more
semanticscholar +1 more source
FGF23 production by osteocytes [PDF]
Pediatric Nephrology, 2012 Fibroblast growth factor 23 (FGF23), a known regulator of phosphate homeostasis, is produced by cells residing in bone, namely, osteocytes, to target a distant organ, the kidney. Elevated FGF23 levels have recently been found systemically and in osteocytes in patients and animal models of chronic kidney disease.
Lynda F, Bonewald, Michael J, Wacker
openaire +2 more sources
Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
JCRPE, 2022 X-linked hypophosphatemia (XLH) is a rare genetic disorder with X-linked dominant inheritance. Mutations in the PHEX gene increase fibroblast growth factor 23 (FGF23) concentrations, causing loss of phosphorus at the proximal tubule.
Ana Castellano-Martinez +3 more
doaj +1 more source
Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
Frontiers in Cell and Developmental Biology, 2021 Together with fibroblast growth factors (FGFs) 19 and 21, FGF23 is an endocrine member of the family of FGFs. Mainly secreted by bone cells, FGF23 acts as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3 ...
F. Ewendt, M. Feger, M. Föller
semanticscholar +1 more source
FGF23, Hypophosphatemia, and Emerging Treatments [PDF]
JBMR Plus, 2019 ABSTRACTFGF23 is an important hormonal regulator of phosphate homeostasis. Together with its co‐receptor Klotho, it modulates phosphate reabsorption and both 1α‐hydroxylation and 24‐hydroxylation in the renal proximal tubules. The most common FGF23‐mediated hypophosphatemia is X‐linked hypophosphatemia (XLH), caused by mutations in the PHEX gene. FGF23‐
Imel, Erik A. +3 more
openaire +5 more sources
Kidney & Blood Pressure Research, 2021 Introduction: Phosphate homeostasis is regulated by a complex network involving the parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and calcitriol acting on several organs including the kidney, intestine, bone, and parathyroid gland ...
Nicole Gehring +3 more
doaj +1 more source